Opdivo plus Yervoy demonstrated superior median EFS and overall survival rates compared to chemotherapy in resectable NSCLC. The combination therapy showed higher pathologic complete response and ...

Bristol-Myers Squibb's checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology, but has just had a setback. The company says the first readout ...

Opdivo plus Yervoy showed a median overall survival of 23.7 months vs. 20.6 months with lenvatinib or sorafenib in the CheckMate -9DW trial. The overall response rate for Opdivo plus Yervoy was 36 ...

Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab) for another ...

The European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the recombinant human monoclonal antibody Yervoy (ipilimumab ...

Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced ...

Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult ...